The healthcare sector is undergoing a deep transformation. Valuations have normalised, capital is flowing to the most differentiated assets, and artificial intelligence is no longer a selling point: it has become the first thing acquirers screen for. For the leaders of French MedTechs, this environment is rewriting the rules of M&A.
A quieter market that is creating more value
The first quarter of 2026 confirms an underlying trend: total biotech M&A value reached 84 billion dollars in Q1 2026 alone, compared with 44.4 billion a year earlier, the strongest start to a year since 2019. MedTech is following the same path, with announced deals doubling between Q4 2025 and Q1 2026.
Buyers are more selective, but pay more for the assets they go after. Valuations have come back to healthier levels, around 12.5x to 13x operating income. This reset has bridged the gap between sellers and buyers, after a two-year period in which mismatched expectations had frozen the market. Private equity accounted for around 32% of healthcare M&A activity in Q1 2026. For executives who had put a sale or fundraising plan on hold, the window is now open, and it will not stay open forever.
AI, the central catalyst of deals
The potential value of deals targeting AI platforms in life sciences rose by 256% in 2025, making AI the single biggest driver of transactions in MedTech and Digital Health. In France, of the more than 400 digital health companies tracked by France Biotech, 60% now embed artificial intelligence in their products.
How a company structures its health data has become the top valuation criterion, for industrial buyers and funds alike. Two recent transactions show this in practice. Sêmeia, which has just raised 21 million euros, has established itself as a consolidator in remote medical monitoring, backed by real-world clinical data and a profitable model, a rare combination at this stage. Sonomind illustrates a complementary path: 25 years of fundamental research turned into a non-invasive medical device, clinical results showing a reduction of more than 60% in the severity of treatment-resistant depression symptoms, and a 20 million euro Series A closed in May 2026. In both cases, what won investors over was the data, not the technology story.
The Big Pharma patent cliff, a driver of targeted acquisitions
Behind the AI momentum lies an even more powerful force: the pressure on large pharmaceutical groups’ patent portfolios. With in-house R&D under strain, external growth has become the priority lever. To secure a position in a niche innovation, buyers are willing to push valuations higher.
The most recent example comes from France. In March 2026, Servier acquired US biotech Day One Biopharmaceuticals for 2.5 billion dollars, paying a 68% premium over the share price to gain a foothold in paediatric oncology and rare cancers. That kind of premium reflects the structural pressure weighing on Big Pharma and their readiness to pay up for differentiated assets, with strong therapeutic positioning and solid clinical data.
The European Medical Device Regulation (MDR): A Structuring Factor in M&A
The European Medical Device Regulation (MDR) has profoundly transformed M&A dynamics in the sector. Regulatory compliance has become a major criterion in both valuation and due diligence. Companies that have secured their certifications benefit from a tangible competitive advantage, while those facing delays or high implementation costs are experiencing downward pressure on their valuations. This regulation is also driving consolidation across the sector: some SMEs prefer to align with stronger players in order to absorb the requirements of the MDR, the dental prosthetics market, currently undergoing very significant consolidation, is a concrete illustration of this trend. Mastering regulatory risk has thus become a key determinant of transactions.
What this means in practice for executives
60% of industry players expect M&A activity to pick up in 2026, driven by oncology, rare diseases and cardiometabolic health. Private equity should remain a major engine, with substantial dry powder allocated to high-growth segments.
In this environment, three factors set apart the deals that attract a premium buyer from those that stall.
- Clinical robustness first: data published in leading peer-reviewed journals carries more weight than any financial projection.
- Structured data: an asset that can show a measurable reduction in hospitalisations or in clinicians’ workload has an argument industrial buyers grasp and price in directly.
- Deal preparation: bringing AI into due diligence shortens timelines and tightens the screen. Files that are not properly prepared are weeded out earlier and faster than before.
2026 is shaping up to be a decisive year. Normalised valuations, patent cliff pressure and the premium placed on assets built around data and AI are opening a rare window. The companies that can combine clinical robustness, demonstrated economic impact and a well-prepared financial structure will capture most of the value.
